STOCK TITAN

[144] Surgery Partners, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Surgery Partners, Inc. (SGRY) Rule 144 notice shows an insider intends to sell 25,000 newly acquired common shares through UBS Financial Services on 10/08/2025 with an aggregated market value of $513,185.65 based on 128,209,410 shares outstanding. The shares were acquired the same day as an equity option exercise from the company.

The filing also lists multiple recent sales by Wayne DeVeydt totaling numerous transactions between 08/21/2025 and 09/29/2025, including blocks of 100,000, 150,000, and other quantities with individual gross proceeds shown. The filer certifies no undisclosed material adverse information is known at signing.

Surgery Partners, Inc. (SGRY) avviso della Regola 144 indica che un insider intende vendere 25.000 azioni comuni recentemente acquisite tramite UBS Financial Services il 10/08/2025 per un valore di mercato aggregato di $513,185.65 basato su 128,209,410 azioni in circolazione. Le azioni sono state acquisite lo stesso giorno di un esercizio di opzione azionaria da parte della società.

La pratica elenca anche diverse vendite recenti di Wayne DeVeydt per un totale di numerose transazioni tra 08/21/2025 e 09/29/2025, inclusi blocchi di 100.000, 150.000 e altre quantità con i relativi proventi lordi mostrati. Il dichiarante certifica che non è nota alcuna informazione materiale avversa non divulgata al momento della firma.

Surgery Partners, Inc. (SGRY) el aviso de la Regla 144 muestra que un insider tiene la intención de vender 25,000 acciones comunes recién adquiridas a través de UBS Financial Services el 10/08/2025 con un valor de mercado agregado de $513,185.65 basado en 128,209,410 acciones en circulación. Las acciones fueron adquiridas el mismo día que un ejercicio de opción sobre acciones de la empresa.

El archivo también enumera varias ventas recientes de Wayne DeVeydt por un total de numerosas transacciones entre 08/21/2025 y 09/29/2025, incluyendo bloques de 100,000, 150,000 y otras cantidades con los importes brutos individuales mostrados. El informante certifica que no se conoce información adversa material no divulgada al firmar.

Surgery Partners, Inc. (SGRY) 규칙 144 공지는 내부자가 25,000의 신규 취득 보통주를 UBS Financial Services를 통해 10/08/2025에 매도할 의사가 있음을 보여주며 총 시가 가치는 $513,185.65이며 발행 주식 수 128,209,410주를 기준으로 합니다. 주식은 회사의 주식 옵션 행사와 같은 날에 취득되었습니다.

또한 제출서는 Wayne DeVeydt의 최근 다수의 매도가 08/21/202509/29/2025 사이에 다수의 거래로 합산되며, 100,000, 150,000 등의 블록과 기타 수량이 각각의 총수익과 함께 표시됩니다. 서류 담당자는 서명 시 미공개 주요 악재 정보가 없다고 인증합니다.

Surgery Partners, Inc. (SGRY) avis Rule 144 indique qu'un initié a l'intention de vendre 25 000 actions ordinaires nouvellement acquises via UBS Financial Services le 10/08/2025 pour une valeur marchande agrégée de $513,185.65 basé sur 128,209,410 actions en circulation. Les actions ont été acquises le même jour qu'un exercice d'option sur actions de la société.

Le dossier répertorie également plusieurs ventes récentes de Wayne DeVeydt totalisant de nombreuses transactions entre 08/21/2025 et 09/29/2025, incluant des blocs de 100 000, 150 000, et d'autres quantités avec les produits bruts individuels indiqués. Le déclarant certifie qu'aucune information material adverse non divulguée n'est connue au moment de la signature.

Surgery Partners, Inc. (SGRY) Rule-144-Mitteilung zeigt, dass ein Insider beabsichtigt, 25.000 neu erworbene Stammaktien über UBS Financial Services am 10/08/2025 zu verkaufen, mit einem aggregierten Marktwert von $513,185.65 basierend auf 128,209,410 ausstehenden Aktien. Die Aktien wurden am gleichen Tag wie eine Ausübung einer Aktienoption von der Gesellschaft erworben.

Die Einreichung führt außerdem mehrere kürzliche Verkäufe von Wayne DeVeydt auf, die insgesamt zahlreiche Transaktionen zwischen 08/21/2025 und 09/29/2025 umfassen, einschließlich Blöcken von 100.000, 150.000 und anderen Mengen mit den jeweiligen Bruttoerlösen. Der Einreicher bestätigt, dass zum Zeitpunkt der Unterzeichnung keine unbekannten wesentlichen negativen Informationen bekannt sind.

Surgery Partners, Inc. (SGRY) يوضح إخطار القاعدة 144 أن شخصاً مطلعاً يعتزم بيع 25,000 من الأسهم العادية التي تم اكتسابها حديثاً من خلال UBS Financial Services في 10/08/2025 بقيمة سوقية إجمالية قدرها $513,185.65 استناداً إلى 128,209,410 سهم مُصدر. تم اكتساب الأسهم في اليوم نفسه كتطبيق لخيار أسهم من الشركة.

كما تسرد الإيداع عدة مبيعات حديثة لـ Wayne DeVeydt بإجمالي عدد من المعاملات بين 08/21/2025 و 09/29/2025، بما في ذلك كتل من 100,000، 150,000 وغيرها من الكميات مع عوائد الإجمال الفردية المعروضة. يؤكد مقدم الطلب أنه لا توجد معلومات سلبية مادية غير معلنة عند التوقيع.

Surgery Partners, Inc. (SGRY) 第144条通知显示内部人士拟通过 UBS Financial Services10/08/2025 出售 25,000 股新近取得的普通股,综合市值为 $513,185.65,基于流通在外的 128,209,410 股。该等股份与公司的一项 股票期权行权 同日取得。

该披露还列出 Wayne DeVeydt 的多笔最近出售,总计在 08/21/202509/29/2025 之间的多笔交易,其中包含 100,000150,000 股等区块及其他数量,均显示各自的毛利。申报人声明在签字时未知悉任何未披露的重大不利信息。

Positive
  • Securities were acquired via an equity option exercise, indicating legitimate compensation rather than external purchase
  • Proposed sale amount (25,000 shares, $513,185.65) is small relative to the 128,209,410 shares outstanding
Negative
  • Multiple recent large sales by Wayne DeVeydt between 08/21/2025 and 09/29/2025 may indicate continued insider monetization
  • Concentrated blocks (100,000; 150,000 shares) in prior transactions generated sizeable gross proceeds and could have added short-term supply

Insights

TL;DR: Insider exercised options and plans a 25,000-share sale; several sizeable recent disposals by the same person are disclosed.

The filing reports an equity option exercise and an immediate proposed sale of 25,000 common shares via UBS Financial Services on 10/08/2025

Recent sales by Wayne DeVeydt from 08/21/2025 to 09/29/2025 include multiple large blocks (e.g., 100,000, 150,000) with gross proceeds listed; this indicates ongoing monetization of holdings and creates potential short-term supply into the market. Watch for additional Form 4/Form 144 filings in the near term to confirm ongoing selling pace.

TL;DR: The single 25,000-share sale is modest versus outstanding float, but cumulative recent sales are larger and could be locally marketable.

The announced $513,185.65 market value for 25,000 shares is small relative to 128,209,410 shares outstanding, implying limited company-level dilution or impact from this specific block. However, the historical sales listed include much larger blocks whose cumulative gross proceeds sum materially higher and could affect short-term liquidity or trading flows.

Monitor daily volume around 10/08/2025 and any follow-up sales filings to gauge whether selling pressure persists within the coming days.

Surgery Partners, Inc. (SGRY) avviso della Regola 144 indica che un insider intende vendere 25.000 azioni comuni recentemente acquisite tramite UBS Financial Services il 10/08/2025 per un valore di mercato aggregato di $513,185.65 basato su 128,209,410 azioni in circolazione. Le azioni sono state acquisite lo stesso giorno di un esercizio di opzione azionaria da parte della società.

La pratica elenca anche diverse vendite recenti di Wayne DeVeydt per un totale di numerose transazioni tra 08/21/2025 e 09/29/2025, inclusi blocchi di 100.000, 150.000 e altre quantità con i relativi proventi lordi mostrati. Il dichiarante certifica che non è nota alcuna informazione materiale avversa non divulgata al momento della firma.

Surgery Partners, Inc. (SGRY) el aviso de la Regla 144 muestra que un insider tiene la intención de vender 25,000 acciones comunes recién adquiridas a través de UBS Financial Services el 10/08/2025 con un valor de mercado agregado de $513,185.65 basado en 128,209,410 acciones en circulación. Las acciones fueron adquiridas el mismo día que un ejercicio de opción sobre acciones de la empresa.

El archivo también enumera varias ventas recientes de Wayne DeVeydt por un total de numerosas transacciones entre 08/21/2025 y 09/29/2025, incluyendo bloques de 100,000, 150,000 y otras cantidades con los importes brutos individuales mostrados. El informante certifica que no se conoce información adversa material no divulgada al firmar.

Surgery Partners, Inc. (SGRY) 규칙 144 공지는 내부자가 25,000의 신규 취득 보통주를 UBS Financial Services를 통해 10/08/2025에 매도할 의사가 있음을 보여주며 총 시가 가치는 $513,185.65이며 발행 주식 수 128,209,410주를 기준으로 합니다. 주식은 회사의 주식 옵션 행사와 같은 날에 취득되었습니다.

또한 제출서는 Wayne DeVeydt의 최근 다수의 매도가 08/21/202509/29/2025 사이에 다수의 거래로 합산되며, 100,000, 150,000 등의 블록과 기타 수량이 각각의 총수익과 함께 표시됩니다. 서류 담당자는 서명 시 미공개 주요 악재 정보가 없다고 인증합니다.

Surgery Partners, Inc. (SGRY) avis Rule 144 indique qu'un initié a l'intention de vendre 25 000 actions ordinaires nouvellement acquises via UBS Financial Services le 10/08/2025 pour une valeur marchande agrégée de $513,185.65 basé sur 128,209,410 actions en circulation. Les actions ont été acquises le même jour qu'un exercice d'option sur actions de la société.

Le dossier répertorie également plusieurs ventes récentes de Wayne DeVeydt totalisant de nombreuses transactions entre 08/21/2025 et 09/29/2025, incluant des blocs de 100 000, 150 000, et d'autres quantités avec les produits bruts individuels indiqués. Le déclarant certifie qu'aucune information material adverse non divulguée n'est connue au moment de la signature.

Surgery Partners, Inc. (SGRY) Rule-144-Mitteilung zeigt, dass ein Insider beabsichtigt, 25.000 neu erworbene Stammaktien über UBS Financial Services am 10/08/2025 zu verkaufen, mit einem aggregierten Marktwert von $513,185.65 basierend auf 128,209,410 ausstehenden Aktien. Die Aktien wurden am gleichen Tag wie eine Ausübung einer Aktienoption von der Gesellschaft erworben.

Die Einreichung führt außerdem mehrere kürzliche Verkäufe von Wayne DeVeydt auf, die insgesamt zahlreiche Transaktionen zwischen 08/21/2025 und 09/29/2025 umfassen, einschließlich Blöcken von 100.000, 150.000 und anderen Mengen mit den jeweiligen Bruttoerlösen. Der Einreicher bestätigt, dass zum Zeitpunkt der Unterzeichnung keine unbekannten wesentlichen negativen Informationen bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Surgery Partners (SGRY) report?

It reports a proposed sale of 25,000 common shares via UBS Financial Services on 10/08/2025 with an aggregate market value of $513,185.65.

How were the 25,000 shares acquired according to the filing?

The filing states the shares were acquired on 10/08/2025 through equity compensation via an equity option exercise from Surgery Partners, Inc.

Who has been selling Surgery Partners stock recently?

The filing lists multiple sales by Wayne DeVeydt from 08/21/2025 to 09/29/2025, including transactions of 100,000 and 150,000 shares.

Does the filing indicate any undisclosed material information?

By signing the notice, the person represents they have no known material adverse information about the issuer that has not been publicly disclosed.

Where will the proposed sale be executed?

The proposed sale is to be executed on NASDAQ through UBS Financial Services Inc.
Surgery Partners Inc

NASDAQ:SGRY

SGRY Rankings

SGRY Latest News

SGRY Latest SEC Filings

SGRY Stock Data

2.61B
76.41M
1.45%
113.98%
9.89%
Medical Care Facilities
Services-general Medical & Surgical Hospitals, Nec
Link
United States
BRENTWOOD